Parkman Healthcare Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Parkman Healthcare Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.4M	Buy	+85,062	New	+$4.33M	0.45%	64
2024 Q1	–	Sell	-119,417	Closed	-$3.46M	–	113
2023 Q4	$3.46M	Sell	119,417 -18,755	-14%	-$497K	0.49%	62
2023 Q3	$3.81M	Sell	138,172 -52,007	-27%	-$1.58M	0.7%	40
2023 Q2	$5.72M	Buy	190,179 +58,301	+44%	+$2.04M	0.99%	31
2023 Q1	$4.78M	Buy	131,878 +36,972	+39%	+$1.42M	1.04%	38
2022 Q4	$3.39M	Buy	94,906 +5,197	+6%	+$181K	0.9%	43
2022 Q3	$3.04M	Buy	89,709 +1,051	+1%	+$34.2K	0.86%	44
2022 Q2	$2.56M	Sell	88,658 -20,296	-19%	-$581K	0.94%	38
2022 Q1	$3.52M	Buy	108,954 +4,240	+4%	+$130K	1.03%	36
2021 Q4	$3.05M	Buy	104,714 +4,299	+4%	+$130K	0.67%	41
2021 Q3	$2.68M	Hold	100,415	–	–	0.68%	46
2021 Q2	$3.09M	Buy	+100,415	New	+$3.08M	0.68%	46

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkman Healthcare Partners's SUPN Position: Q1 2026 in Review

Parkman Healthcare Partners opened a new position in Supernus Pharmaceuticals (SUPN) in Q1 2026: 85,062 shares worth $4.4M. The stake represents 0.45% of the portfolio and ranks #64 among its holdings. This is a return to the name: Parkman Healthcare Partners previously reported a position in SUPN as recently as Q4 2023.

Parkman Healthcare Partners first reported a position in SUPN in Q2 2021 and has held it in 12 quarters since. The position peaked at $5.72M in Q2 2023. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Parkman Healthcare Partners held 85,062 shares of Supernus Pharmaceuticals worth $4.4M as of Q1 2026.
Supernus Pharmaceuticals was a new Parkman Healthcare Partners position in Q1 2026.
Supernus Pharmaceuticals made up 0.45% of Parkman Healthcare Partners's portfolio in Q1 2026, its #64 holding.
Parkman Healthcare Partners first reported a position in Supernus Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
Parkman Healthcare Partners's Supernus Pharmaceuticals position peaked at $5.72M in Q2 2023.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.